Cargando…
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma
The emergence of drug resistance continues to be a major hurdle towards improving patient outcomes for the treatment of Multiple Myeloma. MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 containing complex and triggers necrotic cell death in multiple myeloma cell lines. In this rep...
Autores principales: | Emmons, Michael F., Anreddy, Nagaraju, Cuevas, Javier, Steinberger, Kayla, Yang, Shengyu, McLaughlin, Mark, Silva, Ariosto, Hazlehurst, Lori A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457439/ https://www.ncbi.nlm.nih.gov/pubmed/28578393 http://dx.doi.org/10.1038/s41598-017-02713-0 |
Ejemplares similares
-
Transient Receptor Potential C 1/4/5 Is a Determinant of MTI-101 Induced Calcium Influx and Cell Death in Multiple Myeloma
por: Elzamzamy, Osama M., et al.
Publicado: (2021) -
Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic β‐hairpin‐like scaffold, MTI‐101
por: Jain, Priyesh, et al.
Publicado: (2020) -
Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines
por: Jones, Clark, et al.
Publicado: (2022) -
The Role of TRPC1 in Modulating Cancer Progression
por: Elzamzamy, Osama M, et al.
Publicado: (2020) -
Bridging the gap – MTI experience to an excellent MTI experience – An experiential, theme driven, concordance verifying study
por: Enara, Arun, et al.
Publicado: (2021)